Usefulness of central radiologic review in clinical trials of children with hepatoblastoma

Abstract

Background: No previous research papers have reported a comparative survey of local radiologic diagnoses and central review in children with hepatoblastoma.

Objective: To evaluate the utility of central review of children with hepatoblastoma enrolled in a clinical trial.

Materials and methods: The study included 91 children enrolled in a clinical trial conducted by the Japanese Study Group for Pediatric Liver Tumor. We compared the results of the initial pre-treatment extent of tumor (PRETEXT) disease staging performed at local sites with the results obtained on central review to determine the concurrence rates for tumor staging and additional criteria.

Results: The concurrence rate for PRETEXT staging was 70%. As the stage increased, the concurrence rate decreased. Using additional criteria, central review identified 143 lesions (157.1%), about 1.8 times higher than the number identified for the local site diagnoses. The additional criterion found most often on central review was "multifocal lesion" (n=19). The concurrence rate for lung metastases was high. However, our central review found many false-positive assertions of hepatic vein lesions, portal vein invasion and extrahepatic lesions among the local site diagnoses.

Conclusion: In a clinical trial of hepatoblastoma, central review provided a more precise diagnosis than local site diagnoses with respect to severe PRETEXT stages III and IV cases and other cases including hepatic and portal vein invasion. The central review process appears to be effective and essential for improving the quality of clinical trials.

Keywords: Central review; Children; Criteria; Diagnosis; Hepatoblastoma; Liver; Pre-treatment extent of tumor; Staging; Tumor.